• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

原发化疗后放疗(RAPCHEM):荷兰注册研究中的实践差异(BOOG 2010-03)。

Radiotherapy after primary CHEMotherapy (RAPCHEM): Practice variation in a Dutch registration study (BOOG 2010-03).

机构信息

Maastricht University Medical Centre+, Dept. of Radiation Oncology (Maastro), GROW School for Oncology and Developmental Biology, Netherlands.

Netherlands Comprehensive Cancer Organisation, Dept. Research and Development, Utrecht, Netherlands.

出版信息

Radiother Oncol. 2020 Apr;145:201-208. doi: 10.1016/j.radonc.2020.01.018. Epub 2020 Feb 10.

DOI:10.1016/j.radonc.2020.01.018
PMID:32058873
Abstract

BACKGROUND

We conducted a prospective cohort study in the Netherlands (RAPCHEM: NCT01279304, BOOG 2010-03) in breast cancer (BC) patients treated with primary systemic therapy (PST), followed by surgery and post-operative radiation therapy (RT) according to a predefined consensus-based study-guideline (SG). The aim of the current analysis is to evaluate adherence to the SG.

METHODS

From January 2011 to January 2015, patients with cT1-2N1 BC treated in 17 Dutch RT Centres were included. Patients with four or more suspicious nodes at imaging were excluded. SG recommended whole breast RT for patients treated with breast conserving therapy. SG on loco(-regional) RT were defined for three risk groups based on the ypN status: (1) ypN0 (low-risk): RT breast and no RT after mastectomy; (2) ypN1 (intermediate-risk): RT breast or chest wall; (3) ypN2 (high-risk): RT breast or chest wall, including regional lymph nodes.

RESULTS

We included 848 patients: 292 in the low-risk group; 374 in the intermediate-risk group; 182 in the high-risk group. Overall, 64% of the patients was treated according to the SG; 11% received less RT than the predefined target volumes and 25% received more extensive RT than according to the SG. The largest variation was seen in the intermediate risk group, where only 54% was treated according to the SG.

CONCLUSION

Substantial deviation from the SG for post-operative RT was observed after PST, especially in patients with an intermediate-risk. Future analyses will evaluate outcome of these patients in relation to risk factors and the actual RT given.

摘要

背景

我们在荷兰开展了一项前瞻性队列研究(RAPCHEM:NCT01279304,BOOG 2010-03),纳入了接受原发系统治疗(PST)后进行手术和术后放疗(RT)的乳腺癌(BC)患者,该研究遵循了基于共识的预设研究指南(SG)。本分析旨在评估对 SG 的依从性。

方法

2011 年 1 月至 2015 年 1 月,17 家荷兰放疗中心治疗的 cT1-2N1BC 患者纳入研究。影像学检查提示存在 4 个或更多可疑淋巴结的患者被排除在外。SG 推荐对接受保乳治疗的患者行全乳 RT。基于 ypN 状态,将局部区域 RT 的 SG 定义为三个风险组:(1)ypN0(低危):RT 乳房,乳房切除术不进行 RT;(2)ypN1(中危):RT 乳房或胸壁;(3)ypN2(高危):RT 乳房或胸壁,包括区域淋巴结。

结果

我们纳入了 848 例患者:低危组 292 例;中危组 374 例;高危组 182 例。总体而言,64%的患者按照 SG 治疗;11%的患者接受的 RT 少于预设靶区,25%的患者接受的 RT 比 SG 更广泛。中危组的变化最大,仅有 54%的患者按照 SG 治疗。

结论

在 PST 后,观察到术后 RT 与 SG 存在显著差异,尤其是中危患者。未来的分析将评估这些患者的结局与风险因素和实际接受的 RT 之间的关系。

相似文献

1
Radiotherapy after primary CHEMotherapy (RAPCHEM): Practice variation in a Dutch registration study (BOOG 2010-03).原发化疗后放疗(RAPCHEM):荷兰注册研究中的实践差异(BOOG 2010-03)。
Radiother Oncol. 2020 Apr;145:201-208. doi: 10.1016/j.radonc.2020.01.018. Epub 2020 Feb 10.
2
De-escalation of radiotherapy after primary chemotherapy in cT1-2N1 breast cancer (RAPCHEM; BOOG 2010-03): 5-year follow-up results of a Dutch, prospective, registry study.cT1-2N1期乳腺癌新辅助化疗后放疗降阶梯治疗(RAPCHEM;BOOG 2010-03):一项荷兰前瞻性注册研究的5年随访结果
Lancet Oncol. 2022 Sep;23(9):1201-1210. doi: 10.1016/S1470-2045(22)00482-X. Epub 2022 Aug 8.
3
The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis.新辅助化疗后乳腺癌临床淋巴结阳性患者行乳房切除术和区域淋巴结放疗的影响:国家癌症数据库(NCDB)分析。
Ann Oncol. 2016 May;27(5):818-27. doi: 10.1093/annonc/mdw046. Epub 2016 Feb 9.
4
Indications for Postmastectomy Radiation After Neoadjuvant Chemotherapy in ypN0 and ypN1-3 Axillary Node-Positive Women.新辅助化疗后 ypN0 和 ypN1-3 腋窝淋巴结阳性女性的保乳术后放疗适应证。
Clin Breast Cancer. 2018 Feb;18(1):e107-e113. doi: 10.1016/j.clbc.2017.07.016. Epub 2017 Aug 1.
5
Postmastectomy Radiation Therapy Based on Pathologic Nodal Status in Clinical Node-Positive Stage II to III Breast Cancer Treated with Neoadjuvant Chemotherapy.新辅助化疗治疗的临床Ⅱ至Ⅲ期淋巴结阳性乳腺癌患者基于病理淋巴结状态的乳房切除术后放疗
Int J Radiat Oncol Biol Phys. 2020 Nov 15;108(4):1030-1039. doi: 10.1016/j.ijrobp.2020.06.028. Epub 2020 Jun 23.
6
Patterns of practice of regional nodal irradiation in breast cancer: results of the European Organization for Research and Treatment of Cancer (EORTC) NOdal Radiotherapy (NORA) survey.乳腺癌区域淋巴结照射的实践模式:欧洲癌症研究与治疗组织(EORTC)区域淋巴结放疗(NORA)调查的结果。
Ann Oncol. 2015 Mar;26(3):529-35. doi: 10.1093/annonc/mdu561. Epub 2014 Dec 5.
7
Clinically node negative breast cancer patients undergoing breast conserving therapy, sentinel lymph node procedure versus follow-up: a Dutch randomized controlled multicentre trial (BOOG 2013-08).接受保乳治疗的临床淋巴结阴性乳腺癌患者,前哨淋巴结手术与随访:一项荷兰随机对照多中心试验(BOOG 2013 - 08)
BMC Cancer. 2017 Jul 1;17(1):459. doi: 10.1186/s12885-017-3443-x.
8
The importance of local-regional radiotherapy with conventional or high-dose chemotherapy in the management of breast cancer patients with > or = 10 positive axillary nodes.局部区域放疗联合传统或高剂量化疗在腋窝淋巴结阳性数≥10个的乳腺癌患者管理中的重要性。
Int J Radiat Oncol Biol Phys. 1999 May 1;44(2):273-80. doi: 10.1016/s0360-3016(99)00009-7.
9
Postoperative loco-regional radiation therapy for breast cancer patients with four or more involved lymph nodes or extracapsular extension.对有四个或更多受累淋巴结或包膜外侵犯的乳腺癌患者进行术后局部区域放射治疗。
Isr Med Assoc J. 2005 Jul;7(7):439-42.
10
Predictors of locoregional outcome in HER2-overexpressing breast cancer treated with neoadjuvant chemotherapy.新辅助化疗治疗HER2过表达乳腺癌局部区域转归的预测因素
Am J Clin Oncol. 2015 Aug;38(4):348-52. doi: 10.1097/COC.0b013e31829d1eb8.

引用本文的文献

1
Escalation and De-Escalation of Adjuvant Radiotherapy in Early Breast Cancer: Strategies for Risk-Adapted Optimization.早期乳腺癌辅助放疗的强化与降阶梯:风险适应性优化策略
Cancers (Basel). 2024 Aug 23;16(17):2946. doi: 10.3390/cancers16172946.
2
Prediction of Overall Disease Burden in (y)pN1 Breast Cancer Using Knowledge-Based Machine Learning Model.使用基于知识的机器学习模型预测(y)pN1期乳腺癌的总体疾病负担
Cancers (Basel). 2024 Apr 13;16(8):1494. doi: 10.3390/cancers16081494.
3
Is radiotherapy after primary chemotherapy (RAPCHEM) on the right path to de-escalation?
原发性化疗后放疗(RAPCHEM)是否走上了降级治疗的正确道路?
Ann Transl Med. 2023 Oct 25;11(11):396. doi: 10.21037/atm-23-549. Epub 2023 Feb 23.
4
De-escalating postoperative radiation therapy after primary systemic therapy in cT1-2N1 breast cancer: lesson from the RAPCHEM/BOOG 2010-03 trial.cT1-2N1期乳腺癌在接受初始全身治疗后降低术后放疗强度:来自RAPCHEM/BOOG 2010-03试验的经验教训
Ann Transl Med. 2023 Aug 30;11(10):366. doi: 10.21037/atm-23-1051. Epub 2023 Apr 11.
5
Postmastectomy Radiation Therapy in Patients With Minimally Involved Lymph Nodes: A Review of the Current Data and Future Directions.微小淋巴结受累患者的乳房切除术后放射治疗:当前数据回顾与未来方向
J Breast Cancer. 2022 Feb;25(1):1-12. doi: 10.4048/jbc.2022.25.e6.